• Selected 0.60 mg/m2 as the single dose for the TeLuRide-006 study going forward for patients randomized to EIK1001 treatment, in accord with a recommendation of the independent Data Monitoring Committee (DMC) following a prespecified analysis
  • DMC recommended that the TeLuRide-006 study continue as planned in all other respects

MILLBRAE, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the selection of a dose of 0.60 mg/m2 that will be employed in future for all patients randomized to receive EIK1001 in the TeLuRide-006 trial. This decision aligns with a recommendation from an independent DMC following a prespecified analysis of unblinded data.